MAP2K7 and hepatocellular carcinoma: To further investigate the role of ERK and JNK in the tumor progression of c-Met-positive and c-Met-negative HCCs, we examined the effects that inhibitors of JNK (SP600125, SP) and MEK (the upstream kinase of ERK, PD98059, PD) exerted on cell migration of the two most motile HCCs, HCC372 and HCC329 (c-Met positive and c-Met negative HCC, respectively).